Amicus (FOLD) Q2 Revenue Jumps 22%

Amicus Therapeutics (NASDAQ:FOLD) reported strong Q2 2025 results, with GAAP revenue of $154.7 million (up 22% YoY, beating estimates by $8 million) and non-GAAP EPS of $0.01 (exceeding a -$0.12 estimate), extending its streak of double-digit revenue growth to seventeen consecutive quarters. Despite robust 63% year-over-year sales growth for Pombiliti + Opfolda, its full-year guidance was trimmed due to delayed patient starts and increased UK rebates. The company also strategically licensed U.S. rights for the late-stage DMX-200, contributing to higher operating expenses, but reaffirmed its overall 2025 revenue outlook and maintained its target for positive GAAP net income in the second half.

Analysis

Amicus Therapeutics (NASDAQ:FOLD) delivered a robust financial performance in Q2 2025, significantly surpassing analyst expectations. The company reported GAAP revenue of $154.7 million, a 22.1% year-over-year increase that beat consensus by $8.0 million, and achieved a non-GAAP EPS of $0.01, a notable outperformance against the estimated loss of -$0.12. This result marks the seventeenth consecutive quarter of double-digit revenue growth on a constant currency basis, underscoring sustained commercial momentum. Growth was broad-based, with the core Fabry disease therapy, Galafold, increasing revenue by 16% to $128.9 million. The newer Pompe disease treatment, Pombiliti + Opfolda, saw sales surge 63% to $25.8 million, driven by new country launches. However, this impressive quarterly growth is tempered by the previously lowered full-year 2025 guidance for the product, which projects 50-65% growth due to headwinds from delayed patient starts and increased UK rebate rates. The company is also actively investing in its pipeline, evidenced by a $30 million upfront fee to license DMX-200, which contributed to a 56% rise in non-GAAP operating expenses. Despite these increased costs and operational challenges for Pombiliti + Opfolda, management reaffirmed its full-year total revenue growth outlook of 15-22% and reiterated its target to achieve positive GAAP net income in the second half of 2025, a key inflection point for the company.

Key Decisions for Investors

• Investors should view the strong revenue and earnings beat as a positive confirmation of commercial execution, but must weigh this against the previously lowered guidance for the key growth driver, Pombiliti + Opfolda.
• Monitor operating expense trends closely in the upcoming quarters, as the 56% year-over-year increase, while driven by strategic pipeline investment, needs to be managed effectively to meet the affirmed target of GAAP profitability in H2 2025.
• Pay attention to updates on the Pombiliti + Opfolda launch, specifically regarding patient onboarding rates and the resolution of regional rebate issues, as these factors will determine if the therapy can meet its revised growth expectations.
• The strategic licensing of the late-stage asset DMX-200 introduces a new potential value driver; progress on its pivotal phase 3 trial should be tracked as a key long-term catalyst for portfolio diversification.